AMA-treated tumor spheroids demonstrated suppressed expression levels of β-catenin and its signaling components including TCF-4, NF-κB, and cyclin D1, which provides a partial explanation of how AMA was able to inhibit tumor spheroid formation. This evidence concerns the gene CCND1 and neoplasm.